CompanyCRSPNasdaqZug

CRISPR Therapeutics AG

CRISPR Therapeutics develops CRISPR/Cas9-based therapies for genetic diseases through a collaboration with Vertex.

SEC EDGAR ClinicalTrials.gov crisprtx.com

424B4Sep 28Latest SEC filing

Sep 30Latest story

September 2026

CRISPR Therapeutics registers Phase 1/2 trial of CTX460 for AATD-related emphysema

Sep 30Trial updateCRISPR Therapeutics AG

August 2026

CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertension

Aug 11Trial updateCRISPR Therapeutics AG CTX340

CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial starts

Aug 3Quarterly updateCRISPR Therapeutics AG CTX340